Conference Coverage
Conference Coverage
Advertisement
Cecilia BrownLung Cancer | May 19, 2025
The study is evaluating if hydrogen peroxide in exhaled breath condensate can be used as a biomarker for lung cancer.
Read More
Laura LitwinImmunotherapy in NSCLC | May 16, 2025
Study investigators suggested there may be a “promising therapeutic strategy for advancing NK cell-based immunotherapy."
Cecilia BrownNon-Small Cell Lung Cancer | May 12, 2025
Researchers synthesized circular RNA encoding NY-ESO-1, which is expressed in a proportion of patients with NSCLC.
Alexander Spira, MD, PhDELCC 2025 | May 8, 2025
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Jared Weiss, MDELCC 2025 | May 2, 2025
Dr. Weiss noted the results in both feasibility and safety, particularly via injection, which had limited complications.
Laura LitwinELCC 2025 | May 1, 2025
The study explored the effect of immune checkpoint inhibition on real-world patients with NSCLC versus trial patients.
Cecilia BrownNon-Small Cell Lung Cancer | April 30, 2025
The phase 1 LuCa-MERIT-1 trial is evaluating BNT116, an unmodified RNA-based lipoplex cancer vaccine, with cemiplimab.
Cecilia BrownConference Coverage | April 28, 2025
John V. Heymach, MD, PhD, of the MD Anderson Cancer Center, presented results from the trial at AACR 2025.
Cecilia BrownKRAS+ NSCLC | April 28, 2025
Kathryn C. Arbour, MD, of the Memorial Sloan Kettering Cancer Center, presented results from the study at AACR 2025.
Stephen V. Liu, MDEGFR+ NSCLC | April 24, 2025
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Cecilia BrownELCC 2025 | April 17, 2025
Margarita Majem, MD, PhD, presented the results as a late-breaking abstract during the European Lung Cancer Congress 2025.
Nicolas Girard, MD, PhDELCC 2025 | April 16, 2025
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
Martin Reck, MD, PhDELCC 2025 | April 12, 2025
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Marc Ladanyi, MDELCC 2025 | April 10, 2025
Dr. Ladanyi reflects on genetic hotspot mutations that have not been previously well characterized in lung adenocarcinoma.
Martin Reck, MD, PhDELCC 2025 | April 9, 2025
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Cecilia BrownELCC 2025 | April 4, 2025
Suresh Senan, MRCP, FRCR, PhD, presented the data at the European Lung Cancer Congress 2025 in Paris, France.
Cecilia BrownELCC 2025 | April 3, 2025
Martin Reck, MD, PhD, presented the final analysis at the European Lung Cancer Congress 2025.
Cecilia BrownELCC 2025 | April 1, 2025
Subcutaneous pembrolizumab may be “a viable treatment option" in indications where pembrolizumab is approved.
Cecilia BrownELCC 2025 | March 31, 2025
Andrea Riccardo Filippi, MD, presented survival data from the final PACIFIC-R data extraction with over 5 years of follow-up.
Cecilia BrownELCC 2025 | March 28, 2025
Suresh S. Ramalingam, MD, FACP, FASCO, presented the data during a proffered paper session at ELCC 2025.
Advertisement
Advertisement
Latest News

May 19, 2025